Freeline Therapeutics Holdings KUV 2024

Freeline Therapeutics Holdings는 무엇을 하나요?

Freeline Therapeutics Holdings PLC is a biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company was founded in 2015 and is headquartered in London, United Kingdom. Freeline Therapeutics also has a branch in Munich, Germany. The company focuses on the development and manufacturing of gene therapies using AAV (Adeno-associated viruses) vectors. These vectors serve as delivery vehicles to transport therapeutic genes into cells. Freeline Therapeutics utilizes its expertise in this field to develop innovative gene therapies for patients with rare diseases. Freeline Therapeutics' business model is based on researching, developing, and commercializing gene therapies for rare diseases. The company has several partnerships with other biopharmaceutical companies and academic institutions to advance the development of individual therapeutic approaches. Freeline Therapeutics has three main areas: hemophilia, Krabbe disease, and Fabry disease. In the hemophilia division, Freeline Therapeutics develops gene therapies for patients with hemophilia A and B. The therapy aims to improve the production of the missing clotting factor in the body. Such therapy could reduce or even eliminate the need for repeated infusions required to treat bleeding. In the Krabbe disease division, Freeline Therapeutics is developing a gene therapy for the treatment of Krabbe disease, a rare and life-threatening inherited disorder that affects the central nervous system. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain lipid compounds, thereby slowing down or even stopping the disease. In the Fabry disease division, Freeline Therapeutics is working on developing a gene therapy for the treatment of Fabry disease, a rare disorder that affects the cardiovascular system and other organs. The therapy aims to replace the missing enzyme in the body that enables the breakdown of certain fats, thereby slowing down or even stopping the disease. Freeline Therapeutics has several products in development, including FLT180a, FLT190a, and FLT200, all of which represent gene therapies for different rare diseases. FLT180a is a gene therapy being developed for the treatment of hemophilia A. FLT190a is a gene therapy being developed for the treatment of Krabbe disease. FLT200 is a gene therapy being developed for the treatment of Fabry disease. Freeline Therapeutics also has a pipeline of gene therapies currently in the preclinical phase. The company is committed to accelerating the development of gene therapies for rare diseases and improving patients' access to these innovative treatments. Overall, Freeline Therapeutics is an emerging biopharmaceutical company specializing in the development of gene therapies for rare diseases. The company has expertise in AAV vector technology and aims to develop innovative and life-saving therapies for patients with rare diseases. Freeline Therapeutics Holdings ist eines der beliebtesten Unternehmen auf Eulerpool.com.